Welcome to our dedicated page for Q32 BIO SEC filings (Ticker: QTTB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Q32 Bio Inc. (QTTB) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K that highlight material events. Q32 Bio’s filings reflect its status as a Nasdaq-listed clinical stage biotechnology company focused on alopecia areata and other autoimmune and inflammatory diseases.
Recent Form 8-K filings referenced by Q32 Bio include reports furnished under Item 2.02 for quarterly financial results and corporate updates, and under Item 8.01 for other events such as clinical trial milestones. For example, the company has filed 8-Ks in connection with press releases announcing financial results for specific quarters, as well as an 8-K describing the completion of enrollment in Part B of the SIGNAL-AA Phase 2a clinical trial of bempikibart for alopecia areata. Another 8-K details leadership changes under Item 5.02, including the resignation of a Chief Medical Officer and the appointment of an interim Chief Medical Officer.
Q32 Bio’s 8-K filings also confirm that its common stock, with a par value of $0.0001 per share, is registered pursuant to Section 12(b) of the Exchange Act and trades on Nasdaq under the symbol QTTB. The filings typically attach press releases as exhibits, which are incorporated by reference where specified, and clarify whether the information is being furnished rather than filed for purposes of Section 18 of the Exchange Act.
On Stock Titan, these SEC documents are updated as they become available from EDGAR and are paired with AI-powered summaries that explain the key points in accessible language. Users can quickly see which filings relate to financial results, clinical trial updates, leadership changes, or other corporate events, and can review the underlying forms and exhibits for more detail.
Q32 Bio Inc. director Kathleen LaPorte received a grant of stock options covering 9,810 shares of common stock at an exercise price of $12.64 per share. These options vest in full on the earlier of June 12, 2027 or the company’s next annual stockholder meeting, subject to her continued service, and represent her entire reported option position in this filing.
Q32 Bio Inc. director Mark T. Iwicki received a grant of stock options covering 9,810 shares of common stock. The options have an exercise price of $12.64 per share and expire on June 11, 2036. They vest in full on the earlier of June 12, 2027 or the company’s next annual stockholder meeting, contingent on his continued service.
Q32 Bio Inc. director Isaac Manke received a grant of stock options covering 9,810 shares of common stock. These options have an exercise price of $12.64 per share and were awarded as compensation, not through an open-market purchase or sale.
The options vest and become exercisable in full on the earlier of June 12, 2027 or the date of Q32 Bio’s next annual meeting of stockholders, subject to Manke’s continued board service on that vesting date. Following this grant, he holds 9,810 derivative securities tied to Q32 Bio common stock directly.
Q32 Bio Inc. director Arthur Tzianabos received a grant of stock options representing 9,810 shares of common stock. The options have an exercise price of $12.64 per share and expire on June 11, 2036. Following this grant, he holds 9,810 options directly from this award in this filing.
According to the vesting terms, these options will vest and become exercisable in full on the earlier of June 12, 2027 or the date of Q32 Bio’s next annual meeting of stockholders, provided he continues to serve with the company through the applicable vesting date.
Q32 Bio Inc. director David S. Grayzel received a grant of stock options covering 9,810 shares of common stock at an exercise price of $12.64 per share. These options vest in full on the earlier of June 12, 2027 or the issuer’s next annual stockholder meeting, subject to his continued service. Any proceeds from sales of shares issued upon exercise are to be transferred to Atlas Venture Life Science Advisors, LLC, and Grayzel disclaims ownership except for any pecuniary interest.
Q32 Bio Inc. director Mary Thistle received a grant of stock options representing 9,810 shares of common stock. These options have an exercise price of $12.64 per share and expire on June 11, 2036. Following this grant, she holds 9,810 options directly.
The options vest and become exercisable in full on the earlier of June 12, 2027 or the date of Q32 Bio’s next annual meeting of stockholders, as long as she continues serving on the board through that vesting date.
Q32 Bio Inc. director and ten percent owner Diyong Xu received a grant of stock options covering 9,810 shares of common stock at an exercise price of $12.64 per share. These options expire on June 11, 2036.
The options vest and become exercisable in full on the earlier of June 12, 2027 or the date of Q32 Bio’s next annual meeting of stockholders, subject to Xu’s continued service. Under an agreement with OrbiMed entities, any securities or economic benefits from these options must be transferred to OrbiMed-related funds.
Q32 Bio Inc. director Sven Ante Lundberg received a grant of stock options covering 9,810 shares of common stock. The options have an exercise price of $12.64 per share and expire on June 11, 2036. This is a compensation-related award, not an open-market purchase.
All 9,810 underlying shares will vest and become exercisable in full on the earlier of June 12, 2027 or the date of Q32 Bio’s next annual meeting of stockholders, provided Lundberg continues serving as a director through that vesting date.
Q32 Bio Inc. reported the results of its 2026 Annual Meeting of Stockholders. Stockholders representing 11,833,800 common shares out of 15,629,463 entitled shares, or 75.71% of outstanding shares as of April 15, 2026, were present in person or by proxy.
All three Class II director nominees – Kathleen LaPorte, Jodie Morrison, and Arthur Tzianabos, Ph.D. – were elected to three-year terms ending at the 2029 annual meeting. Stockholders also ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
In addition, stockholders approved, on a non-binding, advisory basis, the compensation of the company’s named executive officers. The report was signed on behalf of the company by Chief Executive Officer Jodie Morrison.
Q32 Bio Inc. disclosed that Atlas Venture Opportunity Fund III, L.P. holds 625,000 shares of its common stock in an initial beneficial ownership report. Related general partners Atlas Venture Associates Opportunity III, L.P. and Atlas Venture Associates Opportunity III, LLC disclaim beneficial ownership except for any pecuniary interest.